PharmaCorp Rx (TSXV:PCRX) EPS (Basic): C$-0.01 (TTM As of Mar. 2026)


TSXV:PCRX PharmaCorp Rx Inc TSXV:PCRX
33 GF Score
Price C$0.52
! 2 Warning Signs
View Full Analysis

What is PharmaCorp Rx EPS (Basic)?

PharmaCorp Rx TSXV:PCRX +1.96% 33 EPS (Basic) is C$-0.01 as of Mar. 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

PharmaCorp Rx's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was C$0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.01.

PharmaCorp Rx's EPS (Diluted) for the three months ended in Mar. 2026 was C$0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.01.

PharmaCorp Rx's EPS without NRI for the three months ended in Mar. 2026 was C$0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.01.

During the past 3 years, the average EPS without NRI Growth Rate was 20.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, PharmaCorp Rx's highest 3-Year average EPS without NRI Growth Rate was 20.60% per year. The lowest was 20.60% per year. And the median was 20.60% per year.

PharmaCorp Rx  (TSXV:PCRX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

PharmaCorp Rx EPS (Basic) Related Terms

PharmaCorp Rx EPS (Basic) Historical Data

* Premium members only.

The historical data trend for PharmaCorp Rx's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCorp Rx EPS (Basic) Chart

PharmaCorp Rx Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
0.00 -0.02 -0.01 -0.01 -0.01

PharmaCorp Rx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.01 0.00
TSXV:PCRX
33GF Score
PharmaCorp Rx Inc TSXV:PCRX
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCorp Rx EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

PharmaCorp Rx's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.422-0)/125.139
=-0.01

PharmaCorp Rx's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0.108-0)/174.082
=0.00

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of C$-0.01 mean?
PharmaCorp Rx (TSXV:PCRX) has a EPS (Basic) of C$-0.01 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on PharmaCorp Rx and its competitors.
Is PharmaCorp Rx's EPS (Basic) too high?
PharmaCorp Rx's current EPS (Basic) is C$-0.01. Overall, PharmaCorp Rx has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's EPS (Basic) compare to competitors?
PharmaCorp Rx's EPS (Basic) of C$-0.01 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Healthcare Providers & Services company?
A good EPS (Basic) depends on the Healthcare Providers & Services industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on PharmaCorp Rx and its competitors. PharmaCorp Rx's current EPS (Basic) is C$-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current EPS (Basic) of C$-0.01. The current EPS (Basic) is C$-0.01. PharmaCorp Rx's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current EPS (Basic) is C$-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCorp Rx Business Description

Address 303 Wellman Lane, Suite 203, Saskatoon, SK, CAN, S7T 0J1
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
33GF Score

Get the complete analysis for TSXV:PCRX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.52
Price